151 related items for PubMed ID: 26222760
41. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
[Abstract] [Full Text] [Related]
42. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
43. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H.
Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
[Abstract] [Full Text] [Related]
44. Kawasaki disease in Sicily: clinical description and markers of disease severity.
Maggio MC, Corsello G, Prinzi E, Cimaz R.
Ital J Pediatr; 2016 Nov 02; 42(1):92. PubMed ID: 27806720
[Abstract] [Full Text] [Related]
45. Circulating platelet-neutrophil aggregates play a significant role in Kawasaki disease.
Ueno K, Nomura Y, Morita Y, Eguchi T, Masuda K, Kawano Y.
Circ J; 2015 Nov 02; 79(6):1349-56. PubMed ID: 25787672
[Abstract] [Full Text] [Related]
46. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ, Jung JW.
Yonsei Med J; 2014 Sep 02; 55(5):1260-6. PubMed ID: 25048483
[Abstract] [Full Text] [Related]
47. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
Arthritis Rheumatol; 2021 Jan 02; 73(1):151-161. PubMed ID: 32779863
[Abstract] [Full Text] [Related]
48. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 02; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
49. Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.
Nagakura A, Morikawa Y, Sakakibara H, Miura M.
J Pediatr; 2017 Jun 02; 185():106-111.e1. PubMed ID: 28343657
[Abstract] [Full Text] [Related]
50. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK, Jindal AK, Johnson N, Prithvi A, Vignesh P, Suri D, Rawat A, Gupta A, Singh S.
Rheumatology (Oxford); 2021 Jul 01; 60(7):3413-3419. PubMed ID: 33221920
[Abstract] [Full Text] [Related]
51. Prediction of intravenous immunoglobulin resistance in patients with Kawasaki disease according to the duration of illness prior to treatment.
Ha KS, Lee J, Lee KC.
Eur J Pediatr; 2020 Feb 01; 179(2):257-264. PubMed ID: 31713683
[Abstract] [Full Text] [Related]
52. [Expression of interleukin-17A in serum of children with intravenous immunoglobulin-resistant Kawasaki disease and its clinical significance].
Li SY, Ding Y.
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar 15; 25(3):244-249. PubMed ID: 36946157
[Abstract] [Full Text] [Related]
53. IgG levels in Kawasaki disease and its association with clinical outcomes.
Yamazaki-Nakashimada MA, Gámez-González LB, Murata C, Honda T, Yasukawa K, Hamada H.
Clin Rheumatol; 2019 Mar 15; 38(3):749-754. PubMed ID: 30343342
[Abstract] [Full Text] [Related]
54. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Yoshikane Y, Okuma Y, Miyamoto T, Hashimoto J, Fukazawa R, Kato T, Takeda A, Suda K, Matsushita T, Hiroe M, Imanaka-Yoshida K.
Pediatr Rheumatol Online J; 2021 Jun 05; 19(1):82. PubMed ID: 34090475
[Abstract] [Full Text] [Related]
55. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection.
Dionne A, Le CK, Poupart S, Autmizguine J, Meloche-Dumas L, Turgeon J, Fournier A, Dahdah N.
PLoS One; 2018 Jun 05; 13(10):e0206001. PubMed ID: 30332473
[Abstract] [Full Text] [Related]
56. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
J Pediatr; 2006 Sep 05; 149(3):336-341. PubMed ID: 16939743
[Abstract] [Full Text] [Related]
57. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
EBioMedicine; 2022 Apr 05; 78():103946. PubMed ID: 35306339
[Abstract] [Full Text] [Related]
58. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
Wang X, Pan SL, DU ZH, Ji ZX, Luo G, Sun HX, Ma SJ.
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr 15; 24(4):399-404. PubMed ID: 35527415
[Abstract] [Full Text] [Related]
59. Predictive value of serum procalcitonin for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study.
Shao S, Luo C, Zhou K, Hua Y, Wu M, Liu L, Liu X, Wang C.
Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):78. PubMed ID: 31775782
[Abstract] [Full Text] [Related]
60. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A.
Circulation; 2006 Jun 06; 113(22):2606-12. PubMed ID: 16735679
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
